EUCTR2016-002856-26-DE进行中（未招募）1 期
A PHASE II, SINGLE-ARMED, MULTICENTER TRIAL OF NEOADJUVANT VISMODEGIB IN PATIENTS WITH LARGE AND/OR RECURRENT RESECTABLE BASAL CELL CARCINOMA - NICCI
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patient aged = 18 years
- •2.Able to participate and willing to give written informed consent including consent for photographs prior to performance of study-related procedures and to comply with the study protocol.
- •3.Patients with at least 1 large (= 2 cm in diameter in head/neck region, = 5 cm for trunk/extremities) basal cell carcinoma (BCC), still resectable, but with increased risk for cosmetic disfigurement or functional defects by assessment of the enrolling physician. Patients with large (as defined above) recurrent basal cell carcinoma are also eligible.
- •4.Patients must be naïve to treatment with vismodegib or other hedgehog pathway inhibitors
- •5.Local histopathologic confirmation of BCC (3 mm punch biopsy)
- •6.Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- •7.Consent to undergo mapping biopsies upon reaching complete response
- •8.Adequate hematologic and organ function, defined by the following laboratory results, to be obtained within 7 days prior to registration and prior to first dose of study drug treatment:
- •Absolute neutrophilic count > 1,0 x 109/L
- •Platelet count = 75 x 109/L
- •Hemoglobin = 8,5 g/dL
- •Albumin = 2.5 g/dL
- •Bilirubin = 1.5 x the upper limit of normal (ULN) or within 3 x ULN for patients with documented Gilbert syndrome
- •AST, ALT, and AP = 3 x ULN
- •Serum creatinine = 1.5 x ULN
- •9.Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use 2 effective forms of contraception during the course of this study. Females have to continue to always use 2 effective forms of contraception for at least 24 months after completion of study therapy, and males for at least 2 months after end of therapy. Breast feeding is likewise not allowed for at least 24 months after completion of study therapy.
- •Females of childbearing potential are defined as sexually mature women without prior hysterectomy and who have had menses within the last 12 months.
- •Females are considered NOT to be of childbearing potential if amenorrheic for >12 months and follicle-stimulating hormone (FSH) level = 40 IU/L.
- •Females who are amenorrheic = 2 years, FSH requirement are waived.
- •Effective forms of contraception includes surgical sterilization, a reliable barrier method with spermicidal, birth control pills, or contraceptive hormone implants
- •Female patients of childbearing potential who desire to have children in the future should be informed about measures regarding conservation of fertility
- •10.Negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential (including pre-menopausal women with tubal ligation).
- •11.Absence of any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the study protocol and follow-up as defined by the treatment discontinuation schedule.
- •12.Agreement not to donate blood or blood products during the study and for at least 24 months after discontinuation of vismodegib. Because vismodegib has been detected in seminal fluid, in addition for men, agreement not donate sperm during the study or for at least 2 months after discontinuation of therapy.
- •13. Optional: Consent to undergo non-invasive imaging examinations by means of confocal laserscan-microscopy (CLSM) and/or optical coherence tomography (OCT), during and after end of study treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age ra
排除标准
- •1.History of prior treatment with vismodegib or any other hedgehog pathway inhibitor.
- •2.Radiotherapy that involved the field of the target lesion(s) within 6 months prior to registration. Only one radiotherapy of the target lesion(s) performed > 6 months prior to registration is allowed. If a second radiotherapy in this field took place, patient will be excluded.
- •3.Any metastatic BCC
- •4.Metatypic BCC
- •5.Known or suspected Gorlin-Goltz syndrome
- •6.Uncontrolled medical illness, including advanced malignancies (no activities of the malignancies in the past 3 years), at the discretion of the Investigator
- •7.History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications
- •8.History or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- •9.Any medical or psychological illness or condition preventing adequate consent or ability to comply with the protocol
- •10.Inability or unwillingness to swallow capsules
- •11.Inability or unwillingness to comply with study and follow-up procedures
- •12.Current severe, uncontrolled systemic disease
- •13.History of malabsorption or other conditions that would interfere with the absorption of the orally applicated study drug
- •14.Pregnant, lactating, or breast feeding women
- •15.Patients with one of the following rare hereditary conditions: galactose intolerance, primary hypolactasia, or glucose-galactose malabsorption
- •16.Participation in another clinical drug study within 28 days before registration
- •17.Known or suspected alcohol or drug abuse in the opinion of the investigator
- •18.Known hypersensitivity reaction to vismodegib or any of the other ingredients of this medicine
- •19.Treatment with St John’s wort (Hypericum perforatum)
研究者
相似试验
进行中（未招募）
1 期
A MULTICENTER TRIAL OF A NEW CUSTOMIZED DOSING (RATIONAL ADJUSTMENT OF DOSE TO REDUCE ADVERSE REACTIONS RADAR” DOSING) OF NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL RECURRENT CANCER PATIENTSOvarian, fallopian tube or primary peritoneal recurrent cancerMedDRA version: 20.0Level: LLTClassification code 10006888Term: Ca ovarySystem Organ Class: 100000004864EUCTR2018-003736-77-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI105
进行中（未招募）
1 期
Clinical study to assess neoadjuvant therapy Peptide Receptor Radionuclide with 177Lu-DOTATATE followed by surgery for resectable pancreatic tumorsResectable pancreatic neuroendocrine tumorsMedDRA version: 21.0Level: LLTClassification code 10067518Term: Pancreatic neuroendocrine tumorSystem Organ Class: 100000004864EUCTR2019-002196-34-ITOSPEDALE SAN RAFFAELE30
进行中（未招募）
不适用
TRIAL PHASE II MULTICENTER FOR CANCER PATIENTS DIAGNOSED WITH OSTEOSARCOMA WITH METASTASIS WHO HAVE ALREADY BEEN TREATED PREVIOUSLYEUCTR2012-001106-26-ESJAVIER MARTÍN BROTO
进行中（未招募）
1 期
Phase 1/2 Study of CLN-081 in Patients with Lung Canceron-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsMedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002409-23-NLCullinan Oncology Inc.369
招募中
1 期
A Phase 1/2 Trial of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung CancerJPRN-jRCT2041230017asermoaddeli Ali10